BioCryst Cash Conversion Cycle from 2010 to 2024

BCRX Stock  USD 7.53  0.07  0.92%   
BioCryst Pharmaceuticals Cash Conversion Cycle yearly trend continues to be fairly stable with very little volatility. Cash Conversion Cycle is likely to outpace its year average in 2024. During the period from 2010 to 2024, BioCryst Pharmaceuticals Cash Conversion Cycle regression line of annual values had r-squared of  0.32 and arithmetic mean of (4,819). View All Fundamentals
 
Cash Conversion Cycle  
First Reported
2010-12-31
Previous Quarter
672.7518148
Current Value
706.39
Quarterly Volatility
K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioCryst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioCryst Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 113.7 M or Selling General Administrative of 209.1 M, as well as many indicators such as Price To Sales Ratio of 3.3, Dividend Yield of 0.0 or Days Sales Outstanding of 59.59. BioCryst financial statements analysis is a perfect complement when working with BioCryst Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of BioCryst Pharmaceuticals Correlation against competitors.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.

Latest BioCryst Pharmaceuticals' Cash Conversion Cycle Growth Pattern

Below is the plot of the Cash Conversion Cycle of BioCryst Pharmaceuticals over the last few years. It is BioCryst Pharmaceuticals' Cash Conversion Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioCryst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Cash Conversion Cycle10 Years Trend
Slightly volatile
   Cash Conversion Cycle   
       Timeline  

BioCryst Cash Conversion Cycle Regression Statistics

Arithmetic Mean(4,819)
Geometric Mean1,772
Coefficient Of Variation(146.06)
Mean Deviation5,336
Median(1,434)
Standard Deviation7,039
Sample Variance49.5M
Range25.1K
R-Value0.57
Mean Square Error36.2M
R-Squared0.32
Significance0.03
Slope891.65
Total Sum of Squares693.6M

BioCryst Cash Conversion Cycle History

2024 706.39
2023 672.75
2022 797.58
2021 -535.52
2020 -2365.2
2019 -941.4
2018 -4666.81

About BioCryst Pharmaceuticals Financial Statements

BioCryst Pharmaceuticals investors use historical fundamental indicators, such as BioCryst Pharmaceuticals' Cash Conversion Cycle, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioCryst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Conversion Cycle 672.75  706.39 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.